Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes

Journal of Nanobiotechnology

Research

Hiroaki Mieda¹  Chiaki Ogino¹  Yuya Nishimura¹  Akihiko Kondo¹  Toshinobu Fujiwara²  Jun Ishii³ 

[1] Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai, Nada, 657-8501, Kobe, Japan;Laboratory of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, 467-8603, Nagoya, Japan;Organization of Advanced Science and Technology, Kobe University, 1-1 Rokkodai, Nada, 657-8501, Kobe, Japan;

关键词: RNA interference;    siRNA;    Hepatitis B virus;    Bio-nanocapsule;    Affibody;    HER2;   

DOI  :  10.1186/1477-3155-11-19

 received in 2013-04-17, accepted in 2013-06-18,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundSmall interfering RNA (siRNA) has attracted attention in the field of nucleic acid medicine as a RNA interference (RNAi) application that leads to gene silencing due to specific messenger RNA (mRNA) destruction. However, since siRNA is unstable in blood and unable to cross the cell membrane, encapsulation of siRNA into a carrier is required.ResultsIn this study, we used a carrier that combined ZHER2-displaying bio-nanocapsule (derived from hepatitis B virus surface antigen) and liposomes in a complex in order to investigate the feasibility of effective and target-cell-specific RNAi applications. As a result, by observing RNAi only in HER2-expressing breast cancer cells, using our proposed methodology, we successfully demonstrated target-cell-specific delivery and effective function expression of siRNA.ConclusionsThese findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.

【 授权许可】

Unknown   
© Nishimura et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.